Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kadri Altundag

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
Annals of Diagnostic Pathology|August 17, 2025
SOX10 and TRPS1 in triple-negative breast cancer: Promise, pitfalls, and the need for broader validationKadri Altundag
Expert Opinion on Emerging Drugs|March 13, 2009
Emerging drugs in metastatic breast cancerOmer Dizdar, Kadri Altundag
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|July 8, 2018
Clinical Associations with ABO Blood Group and Rhesus Blood Group Status in Patients with Breast Cancer: A Nationwide Retrospective Study of 3,944 Breast Cancer Patients in TurkeySerkan Akin, Kadri Altundag
Medical Oncology (Northwood, London, England)|August 31, 2011
Leptin and breast cancer: an overviewMehmet Artac, Kadri Altundag
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|January 17, 2021
Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancerFurkan Sarici, Kadri Altundag
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|November 6, 2015
Excellent clinical outcome of triple-negative breast cancer in younger and older womenNilufer Bulut, Kadri Altundag
International Journal of Clinical and Experimental Medicine|February 18, 2016
Does estrogen receptor determination affect prognosis in early stage breast cancers?Nilufer Bulut, Kadri Altundag
The Oncologist|June 24, 2006
Aromatase inhibitors in breast cancer: an overviewKadri Altundag, Nuhad K Ibrahim
Medical Hypotheses|August 25, 2004
DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patientsOzden Altundag, Kadri Altundag, Mehmet Gunduz
Expert Opinion on Emerging Drugs|November 30, 2011
Emerging drugs in metastatic breast cancer: an updateCagatay Arslan, Kadri Altundag, Omer Dizdar
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Annals of Diagnostic Pathology|August 17, 2025
SOX10 and TRPS1 in triple-negative breast cancer: Promise, pitfalls, and the need for broader validationKadri Altundag
Expert Opinion on Emerging Drugs|March 13, 2009
Emerging drugs in metastatic breast cancerOmer Dizdar, Kadri Altundag
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|July 8, 2018
Clinical Associations with ABO Blood Group and Rhesus Blood Group Status in Patients with Breast Cancer: A Nationwide Retrospective Study of 3,944 Breast Cancer Patients in TurkeySerkan Akin, Kadri Altundag
Medical Oncology (Northwood, London, England)|August 31, 2011
Leptin and breast cancer: an overviewMehmet Artac, Kadri Altundag
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|January 17, 2021
Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancerFurkan Sarici, Kadri Altundag
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|November 6, 2015
Excellent clinical outcome of triple-negative breast cancer in younger and older womenNilufer Bulut, Kadri Altundag
International Journal of Clinical and Experimental Medicine|February 18, 2016
Does estrogen receptor determination affect prognosis in early stage breast cancers?Nilufer Bulut, Kadri Altundag
The Oncologist|June 24, 2006
Aromatase inhibitors in breast cancer: an overviewKadri Altundag, Nuhad K Ibrahim
Medical Hypotheses|August 25, 2004
DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patientsOzden Altundag, Kadri Altundag, Mehmet Gunduz
Expert Opinion on Emerging Drugs|November 30, 2011
Emerging drugs in metastatic breast cancer: an updateCagatay Arslan, Kadri Altundag, Omer Dizdar
Pageof 16